


**THE EUROGLYCOSCIENCE FORUM  
(EUROGLYCOFORUM)**

Standing Committee for Life, Earth and Environmental Sciences (LESC)  
Standing Committee for the Medical Sciences  
(European Medical Research Councils, EMRC)



---

# Introduction

---

The European Science Foundation (ESF) is an independent, non-governmental organisation, the members of which are 79 national funding agencies, research-performing agencies, academies and learned societies from 30 countries.

The strength of ESF lies in the influential membership and in its ability to bring together the different domains of European science in order to meet the challenges of the future.

Since its establishment in 1974, ESF, which has its headquarters in Strasbourg with offices in Brussels and Ostend, has assembled a host of organisations that span all disciplines of science, to create a common platform for cross-border cooperation in Europe.

ESF is dedicated to promote collaboration in scientific research, funding of research and science policy across Europe. Through its activities and instruments ESF has made major contributions to science in a global context. The ESF covers the following scientific domains:

- Humanities
- Life, Earth and Environmental Sciences
- Medical Sciences
- Physical and Engineering Sciences
- Social Sciences
- Marine Sciences
- Materials Science
- Nuclear Physics
- Polar Sciences
- Radio Astronomy
- Space Sciences

Glycoscience, the study of complex carbohydrates, i.e. glycoconjugate glycans, oligosaccharides, or polysaccharides, affects all our lives from the food we eat, the viruses and bacteria that cause infections, the way in which organs develop and are repaired to the pharmacology of chemical and biological therapeutics. Glycoscience is very challenging because of the complexity of biological structures and has been recognised as one of the frontiers in chemical, biological and medical research. The EUROGLYCOFORUM Research Networking Programme seeks to provide a focal point for information and training about this subject, both for the glycoscience and a more general scientific community that requires advice and skills in this area.

The EUROGLYCOFORUM programme aims to build a European network which will be strongly supported by a web-based interface. This resource will form a single gateway for glycoscience in Europe. The interface will enable interchange of ideas between those in the community but will also provide an accessible platform for those outside who wish to know more. Information will be available on all the glycoscience resources available in Europe and worldwide. EUROGLYCOFORUM will work to promote the subject throughout Europe with funding agencies and decision makers to raise awareness and support. A programme of meetings and workshops targeted at young researchers is being established alongside support for teaching activities in the area.

Particular focus of the network will be in the following areas:

- (i) Application of glycoscience in a variety of industries such as food, healthcare, materials, diagnostics and pharmaceuticals.
- (ii) Development of new analytical tools, in particular for high-throughput analysis of carbohydrates and carbohydrate-protein interactions (Glycomics).
- (iii) Understanding of the biosynthesis of carbohydrates – biochemistry of enzymes involved in carbohydrate synthesis and degradation.
- (iv) Production (of structural variants) of glycans and glycoconjugates by chemical or enzymatic methods.
- (v) Bioinformatics – the generation of databases of carbohydrate structures and proteins that interact with carbohydrates with data easily accessible to the general scientific community.

The network will build on the many current activities already taking place in this area and help to coordinate and focus efforts.

The running period of the ESF EUROGLYCOFORUM Research Networking Programme is five years from May 2009 to April 2014.

Cover picture:


Image courtesy of Dr Mark Wormald, Oxford Glycobiology Institute, University of Oxford and Professor Pauline Rudd, NIBRT, Dublin

# Some Current Specific Highlights in the Glycosciences

---

## Disease markers


Currently there is a need for improved disease markers that allow earlier, more specific and convenient diagnosis of a number of conditions. Glycans are present in high abundance on all cell surfaces as well as on bacterial, fungal, parasitic and viral surfaces. They are therefore seen as promising markers for disease. For example, several glycans markers have now been described for various types of cancer which may allow diagnosis at a much earlier stage. Glycan profiling also improves the follow-up of the progression and metastasis of the disease. Because the glycan changes are frequently found also on secreted molecules, diagnosis of body fluids by non-invasive procedures is possible. Current efforts in the glycosciences focus on the development of diagnostic tools to discover novel glycan-based markers. Particularly promising are glycoarray technologies, advanced spectroscopic methods such as mass spectrometry and chromatographic methods.



Cell Surface Glycans – visualisation of surface glycoproteins.  
Courtesy of Glycoforum (glycoforum.gr.jp)

## Developmental biology – stem cells and tissue engineering


Specific cell surface glycans are produced at defined stages in cellular development, and these glycans are important in determining cell fate by influencing the interaction of cells with their local microenvironment. The transient nature and large number of possible glycan structures make glycans ideal for such a role. Studies of glycans and their interactions help in understanding the developmental defects or regeneration following injury. A very good example of this is the surface glycans on stem cells, which are key to their differentiation. Understanding and manipulating glycans on stem cell surfaces and their growth environment will be required as stem cell therapy moves from the lab to the clinic.



Human embryonic stem cells.  
Courtesy of Claire Johnson, Manchester


## Pathogenic infections

Glycans are also very important in many infectious diseases because of their involvement in host invasion. The influenza virus provides an excellent example of the importance of glycans in this respect. Haemagglutinin is a protein on the virus surface that recognises sugars (sialic acids) on human cell surfaces. The specificity of a particular haemagglutinin (classified as H1, H2, etc) against human, swine or bird cell surface glycans determines host specificity of a particular flu strain. Another protein on the virus surface is the enzyme sialidase (neuraminidase N1, N2, etc), which aids virus proliferation by cleaving host cell surface sugars. Current anti-flu therapeutics target these proteins. Bacterial adhesion to human cells also frequently depends on the binding to glycans. For example uropathogenic *E. coli* adheres to galactobiose on the cell surface, while strains causing newborn meningitis bind to sialic acid. Anti-adhesion therapy of bacterial infections targets these activities using oligosaccharide mimics of cell surface glycans. Synthetic oligosaccharide-conjugate vaccines show promising targets to solve immunological problems with polysaccharide vaccines in the battle against bacterial infections.



Glycan receptors for the influenza virus identified by glycan arrays.  
Courtesy of Consortium for Functional Glycomics, La Jolla

# Some Current Specific Highlights in the Glycosciences



IgG glycosylation.  
Courtesy of Max Crispin, Oxford

## Glycopharmaceuticals – drug safety, bio distribution and targeting

An increasing number of biopharmaceuticals are coming into the market, many of which are glycoproteins, i.e. proteins that carry carbohydrate side chains. These may be very important in both the function of the protein and the rate at which it is removed from the circulation. One of the great success stories in glycopharmaceuticals is the recombinant human glycoprotein hormone erythropoietin (EPO – see cover image) which is used as a treatment against anemia, where introducing more glycans carrying sialic acid greatly increased its biological half life. Glycosylation is also important for immunoglobulins and needs to be considered especially when they are not produced in human cells, as is often the case. Several glycosylated antibodies (IgGs) are now in the clinic as anti-cancer treatments. Engineering the glycosylation sites and structures is an important part of developing these biopharmaceuticals as effective drugs in terms of pharmacokinetic and pharmacodynamic properties. Glycosylation will not only influence their interaction with receptors which mediate their activity, but also their clearance or even their antigenic properties in the case of non-human IgG.

## Functional foods


There is increasing evidence that bacterial populations in the large intestine respond to changes in diet, in particular to the type and quantity of dietary carbohydrate. Recent research in the area of prebiotic oligosaccharides and symbiotic combinations with probiotics is leading to a more targeted development of functional food ingredients. Improved molecular techniques for analysis of the gut microflora, new manufacturing biotechnologies, and increased understanding of the metabolism of oli-



gosaccharides by probiotics are facilitating development. It is now feasible to modify complex carbohydrates in food by glycan engineering. This can be performed on a commercial scale if required and is a real possibility for improving the quality of food in the future.

## Inherited errors of metabolism

There are several serious inherited conditions with defects in glycoconjugate glycosylation. Frequently these occur in childhood and are therefore particularly distressing. Such defects in glycosylation are often associated with arrested or unregulated development especially in the neural system. One disease where glycosylation plays an important role is muscular dystrophy and defects in the glycosylation of an important muscle cell component known as alpha-dystroglycan have been identified. More research is required in order to understand exactly how glycans are acting but the ability of cells to recognise one particular type of glycan which may only be expressed in one place at one time could explain how neural cells make complex connections. There are several more diseases collectively known as Congenital Diseases of



Glycosylation of alpha-dystroglycan.  
Courtesy of Pat Hewitt, Nottingham

## Specific Actions

Glycosylation where there is a defect in the biosynthesis of glycans, and lysosomal storage diseases, where there is a defect in the catabolism of glycans.

### Polysaccharide bioengineering

Nature produces a thousand billion tons of biomass materials every year. Polysaccharides, polymers based on carbohydrates, are a major part of the annually produced biomass and only a very small percentage is currently used by humans. Polysaccharides are typically produced by plants and microbes. Advances in chemistry and in bioengineering enable remodelling of natural products on an industrial scale which will allow them to be used in a variety of applications. For example chitosans, which are a family of polymers obtained by controlled de-N-acetylation of chitin, have many potential biomedical applications such as tissue engineering, and is considered safe to use. Recent research has shown it is possible, by genetic engineering to introduce enzymes which modify the molecular architecture and produce novel water soluble forms. It has also been demonstrated that chemically modified chitosan derivatives present the adequate properties for safe use in waste water treatments and, in particular, in biomedical applications such as controlled delivery of drugs or other bioactive agents and tissue engineering. Alginates are another family of marine polysaccharides produced from brown seaweeds and several bacteria. Recent bioengineering has provided alginate-producing bacterial strains which provide alginates with specific sequences not found in Nature, but with enhanced properties for biomedical uses (bioencapsulation, tissue engineering).



Alginate microbead.  
Courtesy of Mentz Indergaard

The following actions are planned during the five-year duration of the EUROGLYCOFORUM Research Networking Programme.

### Workshop on remit and organisation of the forum

This will follow on from the previous workshop and be organised to bring together the EUROGLYCOFORUM Steering Committee and the Chairs of the Euroglycosciences Forum interest groups as established in 2007 namely;

- Education • Glycochemistry • Glycoanalysis • Glycoenzymes
- Glycoimmunology • Glycoinformatics • Health and Disease • Structural Glycobiology
- Glycotechnology • Glycoarrays • Developmental glycobiology and model organisms

### Web-based Directory of European Glycoscience Resources

This is seen as key to the success of the whole Programme and will provide a central resource for anyone who has an interest in glycosciences or wishes to apply it in their own field. We will use the Programme to identify resources in all areas of glycoscience throughout Europe and to make a comprehensive list of these. A mailing list will also be set up to disseminate information. The dedicated website for the Programme is at [www.esf.org/glycoscience](http://www.esf.org/glycoscience).

### Website with interactive forum discussions

The same website will also have an area dedicated to discussion which will be moderated and supported by EUROGLYCOFORUM. There will also be a publication alert service with selected recent publications in the areas with significant developments. These will be summarised and indexed.

### Identify relevant calls in FP7 and other funding agencies

EUROGLYCOFORUM will provide up-to-date information on all open calls which have an element of glycoscience. It will also be able to provide information in various topic areas for those looking for potential partners.

### Establish training workshops

These will be workshops aimed at early stage researchers who want to have a good general knowledge of glycoscience in the 21<sup>st</sup> century and who may be thinking of a career in research in the field. They will include practical sessions where the latest technology in the field will be available. They will run alongside workshops

## Specific Actions

---

funded under the FP7 Marie Curie Initial Training Network Scheme and both activities will be managed as an integrated programme.

In the area of science meetings, EUROGLYCOFORUM offers four opportunities:

- Major meetings in selected areas will bring together those with similar interests in the European glycosciences community. They act as a platform for the presentation of ongoing achievements. The workshops will further encourage collaborative research and teaming-up between different research groups.
- Training workshops and networking activities for younger scientists with a comprehensive programme in glycoscience and practical sessions.
- Virtual internet-based meetings which will allow wide participation.
- The EUROGLYCOFORUM also invites a limited number of proposals from potential organisers of workshops and science meetings on topics with a clear connection to the programme.

## Funding

---

ESF Research Networking Programmes are principally funded by the Foundation's Member Organisations on an *à la carte* basis. EUROGLYCOFORUM is supported by:

- **Fonds zur Förderung der wissenschaftlichen Forschung in Österreich (FWF)**  
*Austrian Science Fund, Austria*
- **Fonds voor Wetenschappelijk Onderzoek-Vlaanderen (FWO)**  
*Research Foundation Flanders, Belgium*
- **Nacionalna zaklada za znanost, visoko školstvo i tehnološki razvoj Republike Hrvatske (NZZ)**  
*The National Foundation of Science, Higher Education and Technological Development of the Republic of Croatia, Croatia*
- **Akademie věd České republiky (ASCR)**  
*Academy of Sciences of the Czech Republic, Czech Republic*
- **Eesti Teadusfond (ETF)**  
*Estonian Science Foundation, Estonia*
- **Suomen Akatemia/Finlands Akademi**  
*Academy of Finland/ Research Council for Biosciences and Environment, Finland*
- **Centre National de la Recherche Scientifique (CNRS)**  
*National Centre for Scientific Research, France*
- **Deutsche Forschungsgemeinschaft (DFG)**  
*German Research Foundation, Germany*
- **Magyar Tudományos Akadémia (MTA)**  
*Hungarian Academy of Sciences, Hungary*
- **Országos Tudományos Kutatási Alapprogramok (OTKA)**  
*Hungarian Scientific Research Fund, Hungary*
- **Irish Research Council for Sciences, Engineering and Technology (IRCSET)**  
*Ireland*
- **Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO)**  
*Netherlands Organisation for Scientific Research, The Netherlands*
- **Norges Forskningsråd**  
*Research Council of Norway, Norway*
- **Polska Akademia Nauk (PAN)**  
*Polish Academy of Sciences, Poland*
- **Fundação para a Ciência e a Tecnologia (FCT)**  
*Foundation for Science and Technology, Portugal*
- **Consiliul National al Cercetării Stiintifice din Invatamantul Superior (CNCSIS)**  
*National University Research Council, Romania*

## Steering Committee

---

- **Agentúra na podporu výskumu a vývoja (APVV)**  
*Slovak Research and Development Agency, Slovak Republic*
- **Consejo Superior de Investigaciones Científicas (CSIC)**  
*Council for Scientific Research, Spain*
- **Comisión Interministerial de Ciencia y Tecnología (CICYT)**  
*Interministerial Committee on Science and Technology, Spain*
- **Vetenskapsrådet (VR)**  
*Swedish Research Council, Sweden*
- **Schweizerischer Nationalfonds (SNF)**  
*Swiss National Science Foundation, Switzerland*
- **Medical Research Council (MRC)**  
*United Kingdom*

**Professor Sabine Flitsch** (Chair)  
School of Chemistry  
Manchester Interdisciplinary Biocentre (MIB)  
131 Princess Street  
Manchester M1 7DN • United Kingdom  
Tel: +44 161 306 5172  
Email: sabine.flitsch@manchester.ac.uk

**Professor Marcus Aebi**  
ETH-Hönggerberg  
Institut für Mikrobiologie • HCI F 407  
Wolfgang-Pauli-Str. 10 • 8093 Zürich • Switzerland  
Tel: +41 44 632 64 13  
Email: aebi@micro.biol.ethz.ch

**Dr Tiina Alamäe**  
University of Tartu  
Riia 23 • 51010 Tartu • Estonia  
Tel: +372 737 501  
Email: talamae@ebc.ee

**Professor Bjørn E. Christensen**  
Department of Biotechnology  
Norwegian University of Science and Technology  
Sem Saelandsvei 6/8 • 7491 Trondheim • Norway  
Tel: +47 73 59 33 27  
Email: B.Christensen@biotech.ntnu.no

**Professor Jana Čopíková**  
Institute of Chemical Technology  
Faculty of Food and Biochemical Technology  
Technická 11903 • 166 28 Prague 6 • Czech Republic  
Tel: +420 220 443 114  
Email: jana.copikova@vscht.cz

**Professor Jukka Finne**  
Department of Medical Biochemistry  
and Molecular Biology  
University of Turku  
Kiinanmyllykatu 10 • 20520 Turku • Finland  
Tel: +358 2 333 7240  
Email: jukka.finne@utu.fi

**Professor Johannes P. Kamerling**  
Bijvoet Center  
Utrecht University • Padualaan 8  
3584 CH Utrecht • The Netherlands  
Email: j.p.kamerling@uu.nl  
GBB  
University of Groningen • Kerklaan 30  
9751 NN Haren • The Netherlands  
Email: j.p.kamerling@rug.nl

**Professor Lena Kjellén**  
Institutionen för medicinsk biokemi och mikrobiologi  
IMBIM Box 582 • 751 23 Uppsala • Sweden  
Tel: +46 18 471 42 17  
Email: lena.kjellen@imbim.uu

# EUROGLYCOFORUM Steering Committee

---

**Professor Horst Kunz**

Institut für Organische Chemie  
Universität of Mainz  
Duesbergweg 10-14 • 55128 Mainz • Germany  
Tel: +49 6131 39 22334/22272  
Email: hokunz@uni-mainz.de

**Professor Gordan Lauc**

Fakmaceutsko-biokemijski fakultet  
A.Kovačića 1 • 10000 Zagreb • Croatia  
Tel: +385 1 4818 757  
Email: glauc@pharma.hr

**Professor Jean-Claude Michalski**

Laboratoire de Glycobiologie Structurale et Fonctionnelle  
UMR 8576 • UFR de Biologie  
Université des Sciences et Technologies de Lille  
59655 Villeneuve d'Ascq cedex • France  
Tel: +33 3 20 43 48 83  
Email: Jean-Claude.Michalski@univ-lille1.fr

**Dr Jan Mucha**

Slovak Academy of Sciences  
Institute of Chemistry • 814 99 Bratislava • Slovakia  
Tel: +421 2 5720 4502  
Email: www.apvv.sk

**Professor Ghislain Opendakker**

Katholieke Universiteit Leuven  
Rega Institute • Molecular Immunology  
Minderbroedersstraat 10  
3000 Leuven • Belgium  
Tel: +32 16 33 73 85  
Email: ghislain.opdenakker@rega.kuleuven.be

**Professor Grażyna Palamarczyk**

Institute of Biochemistry and Biophysics  
Polish Academy of Sciences  
Pawinskiego 5a • 02 106 Warszawa • Poland  
Tel: +48 22 592 21 45  
Email: gp@ibb.waw.pl

**Professor Soledad Penadés**

Laboratorio de Gliconanotecnología  
Nanomaterials Biofuncionales  
Paseo Miramón • 182. Edificio Empresarial C  
Parque Tecnológico de San Sebastián  
20009 San Sebastián • Spain  
Tel: +34 943 00 53 07  
Email: spenades@icbiomagune.es

**Professor Stefana Petrescu**

Institute of Biochemistry of Romanian Academy  
Department of Molecular Cell Biology  
1, Schitu Magureanu Blvd • 050025 Bucharest • Romania  
Tel: +40212239068  
Email: Stefana.Petrescu@biochim.ro

**Professor Amélia Pilar Rauter**

Departamento de Química e Bioquímica  
Faculdade de Ciências da Universidade de Lisboa  
Campo Grande • 1749-016 Lisboa • Portugal  
Tel: +351 21 750 09 52  
Email: aprauter@fc.ul.pt

**Professor Pauline Rudd**

NIBRT Professor of Glycobiology at UCD  
National Institute for Bioprocessing Research and Training  
Conway Institute • University College Dublin • Belfield  
Dublin 4 • Ireland  
Tel: +353 1 716 6725/8  
Email: Pauline.Rudd@nibrt.ie

**Professor Iain B.H. Wilson**

Division of Glycobiology • Department of Biochemistry  
University of Natural Resources and Applied Life Sciences  
Muthgasse 18 • 1190 Vienna • Austria  
Tel: +43 1 36 00 66 541  
Email: iain.wilson@boku.ac.at

**Programme Coordinator****Dr Tony Merry**

Manchester Interdisciplinary Biocentre (MIB)  
131 Princess Street  
Manchester M1 7DN • United Kingdom  
Tel: +44 1608 811022  
Email: anthony.merry@manchester.ac.uk

**Advisory Expert****Professor Serge Pérez**

ESRF • Polygone Scientifique Louis Néel  
6 rue Jules Horowitz • 38000 Grenoble • France  
Tel: +33 4 76 51 40 91  
Email: Serge.Perez@ujf-grenoble.fr

---

**ESF Liaison****Mr Paul Beckers**

*Science*

**Ms Cindy Regnier**

*Administration*

Life, Earth and Environmental Sciences Unit  
European Science Foundation • 1 quai Lezay-Marnésia  
BP 90015 • 67080 Strasbourg cedex • France  
Tel: +33 (0)3 88 76 21 62 • Fax: +33 (0)3 88 37 05 32  
Email: cregnier@esf.org

For the latest information on this Research Networking  
Programme consult the EUROGLYCOFORUM website:  
**[www.esf.org/glycoscience](http://www.esf.org/glycoscience)**